Detection of Long Non-Coding RNA in Archival Tissue: Correlation with Polycomb Protein Expression in Primary and Metastatic Breast Carcinoma

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Chisholm, Karen M ^a   Wan, Yue ^a   Li, Rui ^a   Montgomery, Kelli D ^a   Chang, Howard Y ^a   West, Robert B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; LONG UNTRANSLATED RNA; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; EPIGENETICS; EZH2 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCUS; GENETIC CORRELATION; HIGH THROUGHPUT SCREENING; HOTAIR GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; NCHOXA1 GENE; NCHOXD4 GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN EXPRESSION; RNA ANALYSIS; RNA ISOLATION; TISSUE DISTRIBUTION;

BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; CHROMATIN; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; IN SITU HYBRIDIZATION; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYCOMB-GROUP PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA; RNA, UNTRANSLATED; TREATMENT OUTCOME;

EID: 84868107464     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047998     Document Type: Article

References (27)

1. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, et al. (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39: 237-42.
2. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, et al. (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39: 232-6.
3. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, et al. (2007) Epigenetic stem cell signature in cancer. Nat Genet 39: 157-8.
4. Sparmann A, van Lohuizen M, (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6: 846-56.
5. Laible G, Wolf A, Dorn R, Reuter G, Nislow C, et al. (1997) Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J 16: 3219-32.
6. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, et al. (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268-73.
7. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, et al. (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22: 5323-35.
8. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11.
9. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T, (2006) The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 45: 639-45.
10. Varambally S, Dhanasekaran SM, Zhou M, Barrette TF, Kumar-Sinha C, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-9.
11. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, et al. (2006) Expression of Enhancer of Zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12: 1168-74.
12. Mercer TR, Dinger ME, Mattick JS, (2009) Long non-coding RNAs: insights into function. Nat Rev Genet 10: 155-9.
13. Wapinski O, Chang HY, (2011) Long noncoding RNAs and human disease. Trends Cell Biol 21: 354-61.
14. Chu C, Qu K, Zhong FL, Artandi SE, Chang HY, (2011) Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell 44: 667-78.
15. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, et al. (2011) Integrative annotation of human large intergenic noncoding RNAs reveal global properties and specific subclasses. Genes Dev 25: 1915-1927.
16. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, et al. (2009) Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 106: 11667-72.
17. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, et al. (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464: 1071-6.
18. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, et al. (2007) Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNA. Cell 129: 1311-23.
19. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100: 229-235.
20. Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB, (2008) The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest 88: 591-601.
21. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, et al. (2009) The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 15: 778-87.
22. Webster JA, Beck AH, Sharma M, Espinosa I, Weigelt B, et al. (2010) Variations in stromal signatures in breast and colorectal cancer metastases. J Pathol 222: 158-65.
23. Zhao J, Ohsumi TK, Kung JT, Ogawa Y, Grau DJ, et al. (2010) Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell 40: 939-53.
24. Zeidler M, Kleer CG, (2006) The polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer. J Mol Hist 37: 219-223.
25. Shi B, Liang J, Yang X, Wang Y, Zhao Y, et al. (2007) Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 27: 5105-5119.
26. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, et al. (2009) Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 28: 843-853.
27. Diaz LK, Cryns VL, Fraser Symmans W, Sneige N, (2007) Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anal Pathol 14: 419-30.